Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more
Location: 1 Enterprise Drive, Shelton, CT, 06484-4779, United States | Website: https://www.intensitytherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
8.683M
52 Wk Range
$0.26 - $5.09
Previous Close
$0.32
Open
$0.31
Volume
7,773,047
Day Range
$0.30 - $0.34
Enterprise Value
4.85M
Cash
929K
Avg Qtr Burn
-3.211M
Insider Ownership
23.59%
Institutional Own.
9.99%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INT230-6 Details Advanced Soft tissue sarcomas | Phase 3 Data readout | |
INT230-6 Details Neoadjuvant Triple-negative breast cancer | Phase 2 Data readout |